Leadless Pacemaker CRT System Integration Patent Snapshot
The leadless pacemaker / CRT system integration space is a compact, highly concentrated field of 15 patent families dominated by a single corporate filer, Cardiac Pacemakers Inc. Filing activity peaked in 2017 and has since eased, signalling a mature-to-declining phase with limited new entrant pressure but identifiable adjacent technology gaps.
One player commands the field; the top five account for nearly all recorded activity
Cardiac Pacemakers Inc holds the leading position by a wide margin, ranking first among all filers and accounting for the largest single block of patent records in this niche. Boston Scientific Neuromodulation Corp occupies a distant second position, followed by Shape Medical Systems Inc, Pacesetter Inc, and several individual inventors.
The top five filers collectively represent 93% of the ranked applicants visible in this query’ combined total, a concentration level that leaves minimal competitive headroom for challengers within the existing corpus. The gap between the first-ranked applicant and the second-ranked is substantial, indicating a two-tier structure with a clear leader and a fragmented trailing group.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Cardiac Pacemakers Inc | 30 | |
| 2 | Boston Scientific Neuromodulation Corp | 4 | |
| 3 | Shape Medical Systems Inc | 2 | |
| 4 | Pacesetter Inc | 1 | |
| 5 | Marnfeldt Goran N | 1 | |
| 6 | Griffith Paul J | 1 | |
| 7 | Shi Jess W | 1 | |
| 8 | Dal Molin Renzo | 1 |
The visible position of Cardiac Pacemakers Inc — concentrated in electrotherapy (A61N) and diagnostic/surgical methods (A61B) — suggests that the foundational IP architecture for leadless CRT integration was built primarily by one organisation, creating a significant freedom-to-operate consideration for any entrant seeking to work near the core claims.
The most recent filing years should be interpreted cautiously, as patent applications typically take 18–24 months to publish; apparent absence of activity in 2021 onward may partly reflect publication lag rather than a complete cessation of R&D.
A 2017 filing peak followed by sharp decline; electrotherapy class dominates the technology mix
The annual filing trend and the IPC technology composition together reveal a field that mobilised quickly around a narrow technical core and has since contracted, with the visible class far outweighing any adjacent branch.
Annual filing trend
Filings reached their peak in 2017 and have recorded zero new activity in every subsequent year captured in this dataset. The lifecycle evidence confirms activity has eased from that 2017 peak. Years from 2023 onward are subject to publication lag and should not be read as confirmed cessation.
↗ Hover for values · click a bar to ask EurekaTechnology composition
The A61N (electrotherapy and radiation therapy) class accounts for the largest share of patent records, with A61B (diagnosis and surgery) as the secondary class. All other branches — including digital data processing (G06F), plastics shaping (B29C), and connectors (H01R) — represent small fractions, underscoring how narrowly the technical scope is currently defined.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Leadless pacemaker capsule cardiac resynchronizati…
A leadless pacemaker capsule cardiac resynchronization therapy (CRT) system and method are disclosed. The CRT system includes three leadless pacemaker capsules, each arranged for implantation in one of the right atrium, right ventricle and left ventricle. Each of the leadless pacemaker capsules includes a pressure sensor arranged to measure the blood… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Identifying heart failure patients suitable for re… | 184 |
| 2 | Identifying heart failure patients suitable for re… | 151 |
| 3 | Improved architectures for an implantable medical … | 82 |
| 4 | Identifying heart failure patients suitable for re… | 81 |
| 5 | Adaptive cardiac resynchronization therapy system | 75 |
| 6 | Adaptive resynchronization therapy system | 31 |
| 7 | Leadless pacemaker capsule cardiac resynchronizati… | 27 |
| 8 | Integrated multi-device cardiac resynchronization … | 26 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
Cardiac Pacemakers Inc
Cardiac Pacemakers Inc holds 30 patent records — the largest single block in the corpus — concentrated in electrotherapy (A61N 1) and diagnostic/surgical methods (A61B 5 and A61B 17). This focus covers both the stimulation and sensing dimensions of leadless CRT integration, forming a broad foundational portfolio. No applicant momentum data is available for the recent period, consistent with the field’s decline-stage classification.
30 patent recordsBoston Scientific Neuromodulation Corp
Boston Scientific Neuromodulation Corp holds 4 patent records, split between electrotherapy (A61N 1) and digital data processing (G06F 13). The data processing emphasis distinguishes their technical focus from the pure stimulation/sensing approach of the leader, suggesting an interest in the system-control and communication layer of leadless CRT architecture. Momentum data is not available for the recent period.
4 patent recordsFrequently asked questions
The corpus in scope contains 15 patent families. This is a comparatively small field, and the limited total underscores the niche and technically specialised nature of leadless CRT integration as a distinct patent category.
Cardiac Pacemakers Inc is the clear leader, holding 30 patent records — by far the largest block among all filers. Boston Scientific Neuromodulation Corp is the only other institutional filer of note, with 4 patent records.
The field is classified as Decline. Annual filings peaked in 2017 and have eased back since. This indicates the foundational IP landscape is largely settled, with no evidence of a new filing wave within the dataset.
The United States is the lead jurisdiction, followed by Europe (EPO) and WIPO (PCT), with Canada as the only other named jurisdiction. International coverage beyond North America is limited.
The A61N (electrotherapy) class is visible in, with A61B (diagnosis and surgery) as a secondary class. Sparse adjacent branches include G06F (digital data processing) with 6 patent records, H01R (connectors) with 3, and B29C (plastics shaping) with 3. These lower-count branches represent areas of relative sparsity adjacent to the core.
Collaboration activity is minimal. The only co-applicant pairing recorded in the evidence is ROM RAMI and Sorin CRM, with 2 joint filings. There is no broader co-development ecosystem visible in this dataset.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.